|
| Status |
Public on Dec 04, 2020 |
| Title |
Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia [ATAC-Seq] |
| Organism |
Mus musculus |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
A hallmark of acute myeloid leukemia (AML) is the inability of self-renewing malignant cells to mature into a non-dividing terminally differentiated state. To better understand how chromatin factors such as LSD1 interact with metabolic pathways to support the differentiation blockade, we screened a small molecule library to identify druggable substrates that promote myeloid maturation. We found that differentiation caused by LSD1 inhibition is enhanced by combinatorial perturbation of purine nucleotide salvage and de novo lipogenesis pathways. We used ATAC-seq to determine whether the drug combination induces chromatin changes.
|
| |
|
| Overall design |
ATAC-seq analysis of non-treated cells at beginning of experiment and of vehicle or drug treated cells after 2 days, with 2 biological replicates per condition.
|
| |
|
| Contributor(s) |
Zee B |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Dec 01, 2020 |
| Last update date |
Dec 05, 2020 |
| Contact name |
Barry Zee |
| Organization name |
Boston Children's Hospital
|
| Department |
Newborn Medicine
|
| Lab |
Yang Shi
|
| Street address |
61 Binney Street
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02115 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL21103 |
Illumina HiSeq 4000 (Mus musculus) |
|
| Samples (12)
|
| GSM4950992 |
ER-HOXA9 Non-treated Day 0 rep1 [ATAC-Seq] |
| GSM4950993 |
ER-HOXA9 Non-treated Day 0 rep2 [ATAC-Seq] |
| GSM4950994 |
ER-HOXA9 Veh treated Day 2 rep1 [ATAC-Seq] |
| GSM4950995 |
ER-HOXA9 Veh treated Day 2 rep2 [ATAC-Seq] |
| GSM4950996 |
ER-HOXA9 LSD1i treated Day 2 rep1 [ATAC-Seq] |
| GSM4950997 |
ER-HOXA9 LSD1i treated Day 2 rep2 [ATAC-Seq] |
| GSM4950998 |
ER-HOXA9 6MP treated Day 2 rep1 [ATAC-Seq] |
| GSM4950999 |
ER-HOXA9 6MP treated Day 2 rep2 [ATAC-Seq] |
| GSM4951000 |
ER-HOXA9 CER treated Day 2 rep1 [ATAC-Seq] |
| GSM4951001 |
ER-HOXA9 CER treated Day 2 rep2 [ATAC-Seq] |
| GSM4951002 |
ER-HOXA9 Combo treated Day 2 rep1 [ATAC-Seq] |
| GSM4951003 |
ER-HOXA9 Combo treated Day 2 rep2 [ATAC-Seq] |
|
| This SubSeries is part of SuperSeries: |
| GSE162398 |
Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia |
|
| Relations |
| BioProject |
PRJNA681977 |
| SRA |
SRP295538 |
Less...
More...